• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺相关性眼病进展与管理的当前认识:一项系统评价

Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review.

作者信息

Hodgson Nickisa M, Rajaii Fatemeh

机构信息

Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, NY, USA.

出版信息

Ophthalmol Ther. 2020 Mar;9(1):21-33. doi: 10.1007/s40123-019-00226-9. Epub 2019 Dec 10.

DOI:10.1007/s40123-019-00226-9
PMID:31823232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7054489/
Abstract

Thyroid associated orbitopathy (TAO) is a common diagnosis encountered by ophthalmologists and oculoplastic surgeons. TAO has a varying clinical presentation that can include upper eyelid retraction, restrictive strabismus, proptosis, exposure keratopathy, and optic neuropathy. In this review, we discuss the most recent literature on and the current understanding of the pathophysiology of TAO. We also review available and potential future treatment options for the management of TAO.

摘要

甲状腺相关眼病(TAO)是眼科医生和眼整形外科医生常见的诊断病例。TAO临床表现多样,可包括上睑退缩、限制性斜视、眼球突出、暴露性角膜病变和视神经病变。在本综述中,我们讨论了关于TAO病理生理学的最新文献以及当前的认识。我们还综述了TAO治疗的现有及潜在的未来治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2e/7054489/6ea8b35f7cfa/40123_2019_226_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2e/7054489/11adc83e943a/40123_2019_226_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2e/7054489/6ea8b35f7cfa/40123_2019_226_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2e/7054489/11adc83e943a/40123_2019_226_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b2e/7054489/6ea8b35f7cfa/40123_2019_226_Fig2_HTML.jpg

相似文献

1
Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review.甲状腺相关性眼病进展与管理的当前认识:一项系统评价
Ophthalmol Ther. 2020 Mar;9(1):21-33. doi: 10.1007/s40123-019-00226-9. Epub 2019 Dec 10.
2
Thyroid-associated orbitopathy.甲状腺相关眼病。
Semin Plast Surg. 2007 Feb;21(1):65-73. doi: 10.1055/s-2007-967751.
3
Current and Emerging Treatment Strategies for Graves' Orbitopathy.格雷夫斯眼病的当前和新兴治疗策略。
Drugs. 2019 Feb;79(2):109-124. doi: 10.1007/s40265-018-1045-9.
4
Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.甲状腺相关眼病的临床管理和治疗策略:现状和未来展望。
Curr Eye Res. 2020 Nov;45(11):1325-1341. doi: 10.1080/02713683.2020.1776331. Epub 2020 Jun 21.
5
Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management.甲状腺相关性眼病:对病理生理学、免疫学及治疗的最新见解
Saudi J Ophthalmol. 2011 Jan;25(1):15-20. doi: 10.1016/j.sjopt.2010.11.002. Epub 2010 Nov 11.
6
Optimal management of Graves orbitopathy: a multidisciplinary approach.格雷夫斯眼眶病的优化管理:多学科方法
Neth J Med. 2011 Jul-Aug;69(7):302-8.
7
Not All Orbitopathy Is Graves': Discussion of Cases and Review of Literature.并非所有眼眶病都是格雷夫斯病:病例讨论与文献综述
Front Endocrinol (Lausanne). 2017 Jul 31;8:184. doi: 10.3389/fendo.2017.00184. eCollection 2017.
8
Teprotumumab: a disease modifying treatment for graves' orbitopathy.替普罗单抗:一种用于格雷夫斯眼病的疾病修饰疗法。
Thyroid Res. 2020 Jul 4;13:12. doi: 10.1186/s13044-020-00086-7. eCollection 2020.
9
Thyroid-Associated Orbitopathy: Management and Treatment.甲状腺相关眼病:管理与治疗。
J Binocul Vis Ocul Motil. 2022 Jan-Mar;72(1):32-46. Epub 2021 Dec 7.
10
Survey of common practices among oculofacial surgeons in the Asia-Pacific region: Graves' orbitopathy.亚太地区眼面部外科医生常见做法调查:格雷夫斯眼眶病
Orbit. 2014 Oct;33(5):319-25. doi: 10.3109/01676830.2014.938168. Epub 2014 Aug 14.

引用本文的文献

1
Bone morphogenetic proteins (BMPs) at the forefront of ocular diseases and therapeutics.骨形态发生蛋白(BMPs)在眼部疾病与治疗领域处于前沿地位。
Eye Vis (Lond). 2025 Jul 23;12(1):29. doi: 10.1186/s40662-025-00445-1.
2
Surgical management of patients with corneal lesions due to lid pathologies.眼睑病变所致角膜病变患者的手术治疗
World J Clin Cases. 2025 Jul 6;13(19):101889. doi: 10.12998/wjcc.v13.i19.101889.
3
Effects of pulse glucocorticoid treatment on retinal blood flow in patients with active Graves' orbitopathy.脉冲糖皮质激素治疗对活动性格雷夫斯眼病患者视网膜血流的影响。

本文引用的文献

1
Practice Patterns in Orbital Decompression Surgery Among American Society of Ophthalmic Plastic and Reconstructive Surgery Members.美国眼科整形与重建外科学会成员眼眶减压手术的实践模式
Ophthalmol Ther. 2019 Dec;8(4):541-548. doi: 10.1007/s40123-019-00206-z. Epub 2019 Aug 17.
2
A New Era in the Treatment of Thyroid Eye Disease.甲状腺眼病治疗的新时代。
Am J Ophthalmol. 2019 Dec;208:281-288. doi: 10.1016/j.ajo.2019.07.021. Epub 2019 Aug 1.
3
Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves' Ophthalmopathy: Good Results After Long-Term Follow-Up.
BMC Ophthalmol. 2025 Jul 1;25(1):361. doi: 10.1186/s12886-025-04184-8.
4
Asymmetry Upper Eyelid Retraction of Thyroid Eye Disease: Change of Lateral Flare Sign With the Natural Course of Untreated Disease.甲状腺眼病上睑退缩不对称:未治疗疾病自然病程中外侧光斑征的变化
Scientifica (Cairo). 2025 May 23;2025:1855515. doi: 10.1155/sci5/1855515. eCollection 2025.
5
Combining orbital intensity modulated radiation therapy with periorbital triamcinolone acetonide injection for Graves' orbitopathy.将眼眶调强放射治疗与眶周注射曲安奈德联合用于格雷夫斯眼病。
Int J Ophthalmol. 2025 May 18;18(5):904-911. doi: 10.18240/ijo.2025.05.17. eCollection 2025.
6
The burden of illness in thyroid eye disease: current state of the evidence.甲状腺眼病的疾病负担:证据现状
Front Ophthalmol (Lausanne). 2025 Apr 17;5:1565762. doi: 10.3389/fopht.2025.1565762. eCollection 2025.
7
The role of IL-6 in thyroid eye disease: an update on emerging treatments.白细胞介素-6在甲状腺眼病中的作用:新兴治疗方法的最新进展
Front Ophthalmol (Lausanne). 2025 Apr 14;5:1544436. doi: 10.3389/fopht.2025.1544436. eCollection 2025.
8
Human Papillomavirus and Thyroid Eye Disease.人乳头瘤病毒与甲状腺眼病
JAMA Ophthalmol. 2025 Apr 24. doi: 10.1001/jamaophthalmol.2025.0847.
9
Predictive modeling of graves' orbitopathy activity based on meibomian glands analysis using in vivo confocal microscopy.基于体内共聚焦显微镜下睑板腺分析的格雷夫斯眼眶病活动预测模型
BMC Endocr Disord. 2025 Mar 26;25(1):83. doi: 10.1186/s12902-025-01895-3.
10
Retinal and choroidal microvascular analysis by swept-source optical coherence tomography angiography in thyroid-associated ophthalmopathy (TAO) and hyperthyroidism without clinical signs of TAO.通过扫频源光学相干断层扫描血管造影术对甲状腺相关眼病(TAO)和无TAO临床体征的甲状腺功能亢进症进行视网膜和脉络膜微血管分析。
Ann Med. 2025 Dec;57(1):2478314. doi: 10.1080/07853890.2025.2478314. Epub 2025 Mar 20.
眼眶放射治疗联合糖皮质激素治疗中重度格雷夫斯眼病:长期随访结果良好
Int J Endocrinol Metab. 2019 Jan 27;17(1):e84427. doi: 10.5812/ijem.84427. eCollection 2019 Jan.
4
Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.特罗特鲁单抗,一种胰岛素样生长因子-1 受体拮抗剂抗体,用于治疗活动性甲状腺眼病:以眼球突出为重点。
Eye (Lond). 2019 Feb;33(2):183-190. doi: 10.1038/s41433-018-0321-y. Epub 2018 Dec 21.
5
The expression of interleukin-15 and interleukin-17 in tears and orbital tissues of Graves ophthalmopathy patients.白细胞介素-15 和白细胞介素-17 在格雷夫斯眼病患者的泪液和眼眶组织中的表达。
J Cell Biochem. 2019 Apr;120(4):6299-6303. doi: 10.1002/jcb.27916. Epub 2018 Dec 19.
6
Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.托珠单抗治疗中重度糖皮质激素抵抗性格雷夫斯眼病患者的疗效:一项随机临床试验。
Am J Ophthalmol. 2018 Nov;195:181-190. doi: 10.1016/j.ajo.2018.07.038. Epub 2018 Aug 4.
7
Selenium in Graves Hyperthyroidism and Orbitopathy.格雷夫斯病甲亢及眼眶病中的硒
Ophthalmic Plast Reconstr Surg. 2018 Jul/Aug;34(4S Suppl 1):S105-S110. doi: 10.1097/IOP.0000000000001136.
8
New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor.甲状腺相关眼病认识的新进展及胰岛素样生长因子-I受体的潜在作用
F1000Res. 2018 Feb 1;7:134. doi: 10.12688/f1000research.12787.1. eCollection 2018.
9
Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.托珠单抗作为一种减少类固醇用量的药物用于治疗格雷夫斯眼病。
Am J Ophthalmol Case Rep. 2017 Jul 8;7:146-148. doi: 10.1016/j.ajoc.2017.07.001. eCollection 2017 Sep.
10
Teprotumumab for Thyroid-Associated Ophthalmopathy.替普罗单抗治疗甲状腺相关性眼病
N Engl J Med. 2017 May 4;376(18):1748-1761. doi: 10.1056/NEJMoa1614949.